Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure

The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on at...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2013-04, Vol.5 (4), p.1009-1016
Main Authors: YOON, NAMSIK, CHO, JEONG GWAN, KIM, KYE HUN, PARK, KEUN HO, SIM, DOO SUN, YOON, HYUN JU, HONG, YOUNG JOON, PARK, HYUNG WOOK, KIM, JU HAN, AHN, YOUNGKEUN, JEONG, MYUNG HO, PARK, JONG CHUN
Format: Article
Language:English
Subjects:
angiotensin-II receptor blocker
atrial fibrillation
atrial reverse-remodeling
Cardiac arrhythmia
Cardiovascular disease
Coronary vessels
Enzymes
Experiments
Heart attacks
Heart failure
Kinases
Medical research
Ostomy
Potassium
Prevention
Rodents
Studies
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33
cites cdi_FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33
container_end_page 1016
container_issue 4
container_start_page 1009
container_title Experimental and therapeutic medicine
container_volume 5
creator YOON, NAMSIK
CHO, JEONG GWAN
KIM, KYE HUN
PARK, KEUN HO
SIM, DOO SUN
YOON, HYUN JU
HONG, YOUNG JOON
PARK, HYUNG WOOK
KIM, JU HAN
AHN, YOUNGKEUN
JEONG, MYUNG HO
PARK, JONG CHUN
description The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.
doi_str_mv 10.3892/etm.2013.920
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3628872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1930995745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33</originalsourceid><addsrcrecordid>eNpdkkuPFCEUhYnROJNxdq4NiQtdWC2Pogo2Jjrx0ckkbnRNKOrSzVgFLVCT-BP811J221EJCQS-e3IPB4SeUrLhUrHXUOYNI5RvFCMP0CXtFWsooeLhaU-UpBfoOuc7UofoqJTiMbpgXCjVs-4S_XwHAZy33kwYnANbMo4Om1DnzscCIfvQbLc4gYVDiQkPU7TfIOEYcC5psWVJtdaUtEokuIeUoUkwxxEmH3bYVymcTMG_T1Zxn-0eZm_xHkwq2Bk_LQmeoEfOTBmuT-sV-vrh_ZebT83t54_bm7e3jW3btjQdSNvLoZp3wyBU7cpa0o-DMIYq1zoKIyUWpOSuZWbsSKsMr5XKQtuxgfMr9Oaoe1iGGUYLoVQD-pD8bNIPHY3X_94Ev9e7eK95x6TsWRV4eRJI8fsCuei5OoJpMgHikjWVrBPr-3YVff4feheXFKo9TRUnSom-FZV6daRsijkncOdmKNFrzLrGrNeYdY254s_-NnCG_4RagRdHIB9MGP0Y85mpQg0RDWnrLyGK_wI8drOb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1930995745</pqid></control><display><type>article</type><title>Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure</title><source>PubMed (Medline)</source><creator>YOON, NAMSIK ; CHO, JEONG GWAN ; KIM, KYE HUN ; PARK, KEUN HO ; SIM, DOO SUN ; YOON, HYUN JU ; HONG, YOUNG JOON ; PARK, HYUNG WOOK ; KIM, JU HAN ; AHN, YOUNGKEUN ; JEONG, MYUNG HO ; PARK, JONG CHUN</creator><creatorcontrib>YOON, NAMSIK ; CHO, JEONG GWAN ; KIM, KYE HUN ; PARK, KEUN HO ; SIM, DOO SUN ; YOON, HYUN JU ; HONG, YOUNG JOON ; PARK, HYUNG WOOK ; KIM, JU HAN ; AHN, YOUNGKEUN ; JEONG, MYUNG HO ; PARK, JONG CHUN</creatorcontrib><description>The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2013.920</identifier><identifier>PMID: 23599726</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>angiotensin-II receptor blocker ; atrial fibrillation ; atrial reverse-remodeling ; Cardiac arrhythmia ; Cardiovascular disease ; Coronary vessels ; Enzymes ; Experiments ; Heart attacks ; Heart failure ; Kinases ; Medical research ; Ostomy ; Potassium ; Prevention ; Rodents ; Studies ; Surgery</subject><ispartof>Experimental and therapeutic medicine, 2013-04, Vol.5 (4), p.1009-1016</ispartof><rights>Copyright © 2013, Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2013</rights><rights>Copyright © 2013, Spandidos Publications 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33</citedby><cites>FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628872/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628872/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23599726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YOON, NAMSIK</creatorcontrib><creatorcontrib>CHO, JEONG GWAN</creatorcontrib><creatorcontrib>KIM, KYE HUN</creatorcontrib><creatorcontrib>PARK, KEUN HO</creatorcontrib><creatorcontrib>SIM, DOO SUN</creatorcontrib><creatorcontrib>YOON, HYUN JU</creatorcontrib><creatorcontrib>HONG, YOUNG JOON</creatorcontrib><creatorcontrib>PARK, HYUNG WOOK</creatorcontrib><creatorcontrib>KIM, JU HAN</creatorcontrib><creatorcontrib>AHN, YOUNGKEUN</creatorcontrib><creatorcontrib>JEONG, MYUNG HO</creatorcontrib><creatorcontrib>PARK, JONG CHUN</creatorcontrib><title>Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.</description><subject>angiotensin-II receptor blocker</subject><subject>atrial fibrillation</subject><subject>atrial reverse-remodeling</subject><subject>Cardiac arrhythmia</subject><subject>Cardiovascular disease</subject><subject>Coronary vessels</subject><subject>Enzymes</subject><subject>Experiments</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Kinases</subject><subject>Medical research</subject><subject>Ostomy</subject><subject>Potassium</subject><subject>Prevention</subject><subject>Rodents</subject><subject>Studies</subject><subject>Surgery</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpdkkuPFCEUhYnROJNxdq4NiQtdWC2Pogo2Jjrx0ckkbnRNKOrSzVgFLVCT-BP811J221EJCQS-e3IPB4SeUrLhUrHXUOYNI5RvFCMP0CXtFWsooeLhaU-UpBfoOuc7UofoqJTiMbpgXCjVs-4S_XwHAZy33kwYnANbMo4Om1DnzscCIfvQbLc4gYVDiQkPU7TfIOEYcC5psWVJtdaUtEokuIeUoUkwxxEmH3bYVymcTMG_T1Zxn-0eZm_xHkwq2Bk_LQmeoEfOTBmuT-sV-vrh_ZebT83t54_bm7e3jW3btjQdSNvLoZp3wyBU7cpa0o-DMIYq1zoKIyUWpOSuZWbsSKsMr5XKQtuxgfMr9Oaoe1iGGUYLoVQD-pD8bNIPHY3X_94Ev9e7eK95x6TsWRV4eRJI8fsCuei5OoJpMgHikjWVrBPr-3YVff4feheXFKo9TRUnSom-FZV6daRsijkncOdmKNFrzLrGrNeYdY254s_-NnCG_4RagRdHIB9MGP0Y85mpQg0RDWnrLyGK_wI8drOb</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>YOON, NAMSIK</creator><creator>CHO, JEONG GWAN</creator><creator>KIM, KYE HUN</creator><creator>PARK, KEUN HO</creator><creator>SIM, DOO SUN</creator><creator>YOON, HYUN JU</creator><creator>HONG, YOUNG JOON</creator><creator>PARK, HYUNG WOOK</creator><creator>KIM, JU HAN</creator><creator>AHN, YOUNGKEUN</creator><creator>JEONG, MYUNG HO</creator><creator>PARK, JONG CHUN</creator><general>D.A. Spandidos</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130401</creationdate><title>Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure</title><author>YOON, NAMSIK ; CHO, JEONG GWAN ; KIM, KYE HUN ; PARK, KEUN HO ; SIM, DOO SUN ; YOON, HYUN JU ; HONG, YOUNG JOON ; PARK, HYUNG WOOK ; KIM, JU HAN ; AHN, YOUNGKEUN ; JEONG, MYUNG HO ; PARK, JONG CHUN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>angiotensin-II receptor blocker</topic><topic>atrial fibrillation</topic><topic>atrial reverse-remodeling</topic><topic>Cardiac arrhythmia</topic><topic>Cardiovascular disease</topic><topic>Coronary vessels</topic><topic>Enzymes</topic><topic>Experiments</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Kinases</topic><topic>Medical research</topic><topic>Ostomy</topic><topic>Potassium</topic><topic>Prevention</topic><topic>Rodents</topic><topic>Studies</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YOON, NAMSIK</creatorcontrib><creatorcontrib>CHO, JEONG GWAN</creatorcontrib><creatorcontrib>KIM, KYE HUN</creatorcontrib><creatorcontrib>PARK, KEUN HO</creatorcontrib><creatorcontrib>SIM, DOO SUN</creatorcontrib><creatorcontrib>YOON, HYUN JU</creatorcontrib><creatorcontrib>HONG, YOUNG JOON</creatorcontrib><creatorcontrib>PARK, HYUNG WOOK</creatorcontrib><creatorcontrib>KIM, JU HAN</creatorcontrib><creatorcontrib>AHN, YOUNGKEUN</creatorcontrib><creatorcontrib>JEONG, MYUNG HO</creatorcontrib><creatorcontrib>PARK, JONG CHUN</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YOON, NAMSIK</au><au>CHO, JEONG GWAN</au><au>KIM, KYE HUN</au><au>PARK, KEUN HO</au><au>SIM, DOO SUN</au><au>YOON, HYUN JU</au><au>HONG, YOUNG JOON</au><au>PARK, HYUNG WOOK</au><au>KIM, JU HAN</au><au>AHN, YOUNGKEUN</au><au>JEONG, MYUNG HO</au><au>PARK, JONG CHUN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>5</volume><issue>4</issue><spage>1009</spage><epage>1016</epage><pages>1009-1016</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>23599726</pmid><doi>10.3892/etm.2013.920</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-0981
ispartof Experimental and therapeutic medicine, 2013-04, Vol.5 (4), p.1009-1016
issn 1792-0981
1792-1015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3628872
source PubMed (Medline)
subjects angiotensin-II receptor blocker
atrial fibrillation
atrial reverse-remodeling
Cardiac arrhythmia
Cardiovascular disease
Coronary vessels
Enzymes
Experiments
Heart attacks
Heart failure
Kinases
Medical research
Ostomy
Potassium
Prevention
Rodents
Studies
Surgery
title Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A39%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effects%20of%20an%20angiotensin-II%20receptor%20blocker%20on%20structural%20atrial%20reverse-remodeling%20in%20a%20rat%20model%20of%20ischemic%20heart%20failure&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=YOON,%20NAMSIK&rft.date=2013-04-01&rft.volume=5&rft.issue=4&rft.spage=1009&rft.epage=1016&rft.pages=1009-1016&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2013.920&rft_dat=%3Cproquest_pubme%3E1930995745%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c444t-6e8c78b892fbb59ececc07db5aa19f4f1ed10ce883f42ad6049a34449ce462b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1930995745&rft_id=info:pmid/23599726&rfr_iscdi=true